

Rhabdomyosarcoma: Epidemiology Forecasting Intelligence

<https://marketpublishers.com/r/R3A51464E61EN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,500.00 (Single User License)

ID: R3A51464E61EN

Abstracts

CmaxInsight's "Rhabdomyosarcoma-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Rhabdomyosarcoma epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

Incidence and prevalence

Diagnosis rate, treatment rate and mortality patterns

Epidemiology-based forecasting and disease trends

Size of different patient segments in a disease area

Population based: disease occurrence, co-morbidities and treatment patterns

Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment

Patient treatment journey

Treatment algorithm and guidelines

Assesses the disease risk and burden

Highlights the unmet needs

Market driver and barrier

Growth opportunities and market trend analysis

Methodology

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.

To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.

All of the sources used to generate the data and analysis have been identified in the report.

Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.

Contents

1. REPORT INTRODUCTION

2. RHABDOMYOSARCOMA EPIDEMIOLOGY OVERVIEW AT A GLANCE

3. MARKET SHARE DISTRIBUTION OF RHABDOMYOSARCOMA

4. DISEASE BACKGROUND AND OVERVIEW: RHABDOMYOSARCOMA

4.1. Introduction

4.2. Signs and Symptoms

4.3. Etiology

4.4. Risk Factors

4.5. Pathophysiology

4.6. Diagnostic Landscape

4.6.1. Diagnostic Practices

4.6.2. Diagnostic Criteria

4.6.3. Diagnostic Recommendations

4.7. Treatment Landscape

4.7.1. Current Treatment Practices

4.7.2. Treatment Algorithm

4.7.3. Treatment Recommendations

5. RHABDOMYOSARCOMA EPIDEMIOLOGY

5.1. Key Findings

5.2. Assumptions & Rationale

5.3. 7MM Epidemiology

6. EPIDEMIOLOGY OF RHABDOMYOSARCOMA BY COUNTRIES

7. UNITED STATES

7.1. Assumptions and Rationale

7.2. Prevalent/Incident Cases of Rhabdomyosarcoma

7.3. Sub-Type Specific cases of Rhabdomyosarcoma*

7.4. Sex- Specific Cases of Rhabdomyosarcoma*

7.5. Diagnosed Cases of Rhabdomyosarcoma

7.6. Treated Cases of Rhabdomyosarcoma

8. EU5

8.1. Germany

- 8.1.1. Assumptions and Rationale
- 8.1.2. Prevalent/Incident Cases of Rhabdomyosarcoma
- 8.1.3. Sub-Type Specific cases of Rhabdomyosarcoma*
- 8.1.4. Sex- Specific Cases of Rhabdomyosarcoma*
- 8.1.5. Diagnosed Cases of Rhabdomyosarcoma
- 8.1.6. Treated Cases of Rhabdomyosarcoma

8.2. France

- 8.2.1. Assumptions and Rationale
- 8.2.2. Prevalent/Incident Cases of Rhabdomyosarcoma
- 8.2.3. Sub-Type Specific cases of Rhabdomyosarcoma*
- 8.2.4. Sex- Specific Cases of Rhabdomyosarcoma*
- 8.2.5. Diagnosed Cases of Rhabdomyosarcoma
- 8.2.6. Treated Cases of Rhabdomyosarcoma

8.3. United Kingdom

- 8.3.1. Assumptions and Rationale
- 8.3.2. Prevalent/Incident Cases of Rhabdomyosarcoma
- 8.3.3. Sub-Type Specific cases of Rhabdomyosarcoma*
- 8.3.4. Sex- Specific Cases of Rhabdomyosarcoma*
- 8.3.5. Diagnosed Cases of Rhabdomyosarcoma
- 8.3.6. Treated Cases of Rhabdomyosarcoma

8.4. Spain

- 8.4.1. Assumptions and Rationale
- 8.4.2. Prevalent/Incident Cases of Rhabdomyosarcoma
- 8.4.3. Sub-Type Specific cases of Rhabdomyosarcoma*
- 8.4.4. Sex- Specific Cases of Rhabdomyosarcoma*
- 8.4.5. Diagnosed Cases of Rhabdomyosarcoma
- 8.4.6. Treated Cases of Rhabdomyosarcoma

8.5. Italy

- 8.5.1. Assumptions and Rationale
- 8.5.2. Prevalent/Incident Cases of Rhabdomyosarcoma
- 8.5.3. Sub-Type Specific cases of Rhabdomyosarcoma*
- 8.5.4. Sex- Specific Cases of Rhabdomyosarcoma*
- 8.5.5. Diagnosed Cases of Rhabdomyosarcoma
- 8.5.6. Treated Cases of Rhabdomyosarcoma

9. JAPAN

- 9.1. Assumptions and Rationale
- 9.2. Prevalent/Incident Cases of Rhabdomyosarcoma
- 9.3. Sub-Type Specific cases of Rhabdomyosarcoma*
- 9.4. Sex- Specific Cases of Rhabdomyosarcoma*
- 9.5. Diagnosed Cases of Rhabdomyosarcoma
- 9.6. Treated Cases of Rhabdomyosarcoma

10. UNMET NEEDS

Appendix

Report Methodology

Sources Used

Disclaimer

About CmaxInsight

*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.

List Of Tables

LIST OF TABLES

| |
|---|
| Table 1: Total Prevalent/Incident Cases of the Rhabdomyosarcoma in 7MM |
| Table 2: Total Prevalent/Incident Cases of the Rhabdomyosarcoma in 7MM by Countries |
| Table 3: Prevalent/Incident Cases of the Rhabdomyosarcoma in United States |
| Table 4: Sub-Type Specific Cases of the Rhabdomyosarcoma in United States* |
| Table 5: Sex- Specific Cases of the Rhabdomyosarcoma in United States* |
| Table 6: Diagnosed Cases of the Rhabdomyosarcoma in United States |
| Table 7: Treated Cases of the Rhabdomyosarcoma in United States |
| Table 8: Prevalent/Incident Cases of the Rhabdomyosarcoma in Germany |
| Table 9: Sub-Type Specific Cases of the Rhabdomyosarcoma in Germany* |
| Table 10: Sex- Specific Cases of the Rhabdomyosarcoma in Germany* |
| Table 11: Diagnosed Cases of the Rhabdomyosarcoma in Germany |
| Table 12: Treated Cases of the Rhabdomyosarcoma in Germany |
| Table 13: Prevalent/Incident Cases of the Rhabdomyosarcoma in France |
| Table 14: Sub-Type Specific Cases of the Rhabdomyosarcoma in France* |
| Table 15: Sex- Specific Cases of the Rhabdomyosarcoma in France* |
| Table 16: Diagnosed Cases of the Rhabdomyosarcoma in France |
| Table 17: Treated Cases of the Rhabdomyosarcoma in France |
| Table 18: Prevalent/Incident Cases of the Rhabdomyosarcoma in Italy |
| Table 19: Sub-Type Specific Cases of the Rhabdomyosarcoma in Italy* |
| Table 20: Sex- Specific Cases of the Rhabdomyosarcoma in Italy* |
| Table 21: Diagnosed Cases of the Rhabdomyosarcoma in Italy |
| Table 22: Treated Cases of the Rhabdomyosarcoma in Italy |
| Table 23: Prevalent/Incident Cases of the Rhabdomyosarcoma in Spain |
| Table 24: Sub-Type Specific Cases of the Rhabdomyosarcoma in Spain* |
| Table 25: Sex- Specific Cases of the Rhabdomyosarcoma in Spain* |
| Table 26: Diagnosed Cases of the Rhabdomyosarcoma in Spain |
| Table 27: Treated Cases of the Rhabdomyosarcoma in Spain |
| Table 28: Prevalent/Incident Cases of the Rhabdomyosarcoma in UK |
| Table 29: Sub-Type Specific Cases of the Rhabdomyosarcoma in UK* |
| Table 30: Sex- Specific Cases of the Rhabdomyosarcoma in UK* |
| Table 31: Diagnosed Cases of the Rhabdomyosarcoma in UK |
| Table 32: Treated Cases of the Rhabdomyosarcoma in UK |
| Table 33: Prevalent/Incident Cases of the Rhabdomyosarcoma in Japan |
| Table 34: Sub-Type Specific Cases of the Rhabdomyosarcoma in Japan* |

Table 35: Sex- Specific Cases of the Rhabdomyosarcoma in Japan*

Table 36: Diagnosed Cases of the Rhabdomyosarcoma in Japan

Table 37: Treated Cases of the Rhabdomyosarcoma in Japan

*Indication Specific

List Of Figures

LIST OF FIGURES

- Figure 1: Total Prevalent/Incident Cases of the Rhabdomyosarcoma in 7MM
- Figure 2: Total Prevalent/Incident Cases of the Rhabdomyosarcoma in 7MM by Countries
- Figure 3: Prevalent/Incident Cases of the Rhabdomyosarcoma in United States
- Figure 4: Sub-Type Specific Cases of the Rhabdomyosarcoma in United States*
- Figure 5: Sex- Specific Cases of the Rhabdomyosarcoma in United States*
- Figure 6: Diagnosed Cases of the Rhabdomyosarcoma in United States
- Figure 7: Treated Cases of the Rhabdomyosarcoma in United States
- Figure 8: Prevalent/Incident Cases of the Rhabdomyosarcoma in Germany
- Figure 9: Sub-Type Specific Cases of the Rhabdomyosarcoma in Germany*
- Figure 10: Sex- Specific Cases of the Rhabdomyosarcoma in Germany*
- Figure 11: Diagnosed Cases of the Rhabdomyosarcoma in Germany
- Figure 12: Treated Cases of the Rhabdomyosarcoma in Germany
- Figure 13: Prevalent/Incident Cases of the Rhabdomyosarcoma in France
- Figure 14: Sub-Type Specific Cases of the Rhabdomyosarcoma in France*
- Figure 15: Sex- Specific Cases of the Rhabdomyosarcoma in France*
- Figure 16: Diagnosed Cases of the Rhabdomyosarcoma in France
- Figure 17: Treated Cases of the Rhabdomyosarcoma in United France
- Figure 18: Prevalent/Incident Cases of the Rhabdomyosarcoma in Italy
- Figure 19: Sub-Type Specific Cases of the Rhabdomyosarcoma in Italy*
- Figure 20: Sex- Specific Cases of the Rhabdomyosarcoma in Italy*
- Figure 21: Diagnosed Cases of the Rhabdomyosarcoma in Italy
- Figure 22: Treated Cases of the Rhabdomyosarcoma in Italy
- Figure 23: Prevalent/Incident Cases of the Rhabdomyosarcoma in Spain
- Figure 24: Sub-Type Specific Cases of the Rhabdomyosarcoma in Spain*
- Figure 25: Sex- Specific Cases of the Rhabdomyosarcoma in Spain*
- Figure 26: Diagnosed Cases of the Rhabdomyosarcoma in Spain
- Figure 27: Treated Cases of the Rhabdomyosarcoma in Spain
- Figure 28: Prevalent/Incident Cases of the Rhabdomyosarcoma in UK
- Figure 29: Sub-Type Specific Cases of the Rhabdomyosarcoma in UK*
- Figure 30: Sex- Specific Cases of the Rhabdomyosarcoma in UK*
- Figure 31: Diagnosed Cases of the Rhabdomyosarcoma in UK
- Figure 32: Treated Cases of the Rhabdomyosarcoma in UK
- Figure 33: Prevalent/Incident Cases of the Rhabdomyosarcoma in Japan
- Figure 34: Sub-Type Specific Cases of the Rhabdomyosarcoma in Japan*

Figure 35: Sex- Specific Cases of the Rhabdomyosarcoma in Japan*

Figure 36: Diagnosed Cases of the Rhabdomyosarcoma in Japan

Figure 37: Treated Cases of the Rhabdomyosarcoma in Japan

*Indication Specific

I would like to order

Product name: Rhabdomyosarcoma: Epidemiology Forecasting Intelligence

Product link: <https://marketpublishers.com/r/R3A51464E61EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R3A51464E61EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970